{"id":469412,"date":"2021-04-01T06:42:14","date_gmt":"2021-04-01T10:42:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469412"},"modified":"2021-04-01T06:42:14","modified_gmt":"2021-04-01T10:42:14","slug":"genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/","title":{"rendered":"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at <i>Science<\/i>\/AAAS Webinar<\/b><\/p>\n<p>BEIJING&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH) sponsored a <b><i>Science<\/i><\/b>\/AAAS Webinar, \u201cEarly cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment\u201d, which launched today.\n<\/p>\n<p>\nDuring the panel discussion, Genetron Health\u2019s Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled \u201cProfiling cfDNA-based Biomarkers for the Early Detection of Cancer\u201d. In his presentation, Dr. Jiao highlighted the importance of early detection as the most effective method to prevent deaths from cancer.\n<\/p>\n<p>\nHe also outlined the development and features of the Company\u2019s proprietary early screening technology, Mutation Capsule; presented a multi-center prospective study that adopted the Company\u2019s liquid biopsy-based early screening test, HCCscreen<sup>TM<\/sup>; and explained potential R&amp;D pathway for pan-cancer screening assay.\n<\/p>\n<p>\nAccording to the latest data from the Company\u2019s multi-center prospective study for liver cancer, which was released a week before the webinar, HCCscreen<sup>TM<\/sup> had achieved 88% sensitivity and 93% specificity. In early-stage hepatocellular carcinoma patients, the sensitivity of HCCscreen<sup>TM<\/sup> was 85% and 96% for tumor sizes of &lt;3 cm and 3\u20135 cm, respectively.\n<\/p>\n<p>\nDr. Anne Marie Lennon, Director of the Johns Hopkins Division of Gastroenterology and Hepatology and a professor of Medicine at the Johns Hopkins University School of Medicine, joined the conversation with Dr. Jiao. She also emphasized the advantages of liquid biopsy technology in cancer screening, and the benefits of blood tests in particular.\n<\/p>\n<p>\nShe concluded that blood testing makes it possible to detect cancers, including early cancers, even in individuals with no history of the disease. It is possible to intervene on the basis of blood testing, including surgery, she said.\n<\/p>\n<p>\nBlood testing can be incorporated into routine medical care, without discouraging patients from engaging in other forms of screening, she added. Such testing can be performed in a safe manner without incurring a large number of futile, invasive follow-up tests, she said.\n<\/p>\n<p>\nTo watch the webinar, please <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencemag.org%2Fcustom-publishing%2Fwebinars%2Fearly-cancer-screening-today-and-tomorrow-exploring-liquid-biopsy&amp;esheet=52405368&amp;newsitemid=20210401005381&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=823bb44078c2ce33fb7154cef83a48fb\">click here<\/a>.\n<\/p>\n<p><b>About Genetron Holdings Limited<\/b><\/p>\n<p>\nGenetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.\n<\/p>\n<p><b>Safe Harbor Statement<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding business plans, operation outlook and revenue expectation of the HCCscreen\u2122, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company\u2019s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as \u201cmay\u201d, \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cis\/are likely to\u201d or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company\u2019s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210401005381\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210401005381\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contacts<br \/>\n<\/b><br \/>Hoki Luk<br \/>\n<br \/>Head of Investor Relations<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:hoki.luk@genetronhealth.com\">hoki.luk@genetronhealth.com<br \/>\n<\/a><br \/>Phone: +1 (408) 204-5343<\/p>\n<p><b>Media Relations Contact<br \/>\n<\/b><br \/>Yanrong Zhao<br \/>\n<br \/>Genetron Health<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:yanrong.zhao@genetronhealth.com\">yanrong.zhao@genetronhealth.com<br \/>\n<\/a><\/p>\n<p>Edmond Lococo<br \/>\n<br \/>ICR<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Edmond.Lococo@icrinc.com\">Edmond.Lococo@icrinc.com<br \/>\n<\/a><br \/>Mobile: +86 138-1079-1408<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:genetron.pr@icrinc.com\">genetron.pr@icrinc.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> China Asia Pacific<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Research Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar BEIJING&#8211;(BUSINESS WIRE)&#8211; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH) sponsored a Science\/AAAS Webinar, \u201cEarly cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment\u201d, which launched today. During the panel discussion, Genetron Health\u2019s Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled \u201cProfiling cfDNA-based Biomarkers for the Early Detection of Cancer\u201d. In his presentation, Dr. Jiao highlighted the importance of early detection as the most effective method to prevent deaths from cancer. He also outlined the development and features of the Company\u2019s proprietary early screening technology, Mutation Capsule; presented a multi-center prospective study that adopted the Company\u2019s liquid biopsy-based early &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469412","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar BEIJING&#8211;(BUSINESS WIRE)&#8211; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH) sponsored a Science\/AAAS Webinar, \u201cEarly cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment\u201d, which launched today. During the panel discussion, Genetron Health\u2019s Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled \u201cProfiling cfDNA-based Biomarkers for the Early Detection of Cancer\u201d. In his presentation, Dr. Jiao highlighted the importance of early detection as the most effective method to prevent deaths from cancer. He also outlined the development and features of the Company\u2019s proprietary early screening technology, Mutation Capsule; presented a multi-center prospective study that adopted the Company\u2019s liquid biopsy-based early &hellip; Continue reading &quot;Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T10:42:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\\\/AAAS Webinar\",\"datePublished\":\"2021-04-01T10:42:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/\"},\"wordCount\":715,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/\",\"name\":\"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\\\/AAAS Webinar - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-01T10:42:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\\\/AAAS Webinar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/","og_locale":"en_US","og_type":"article","og_title":"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar - Market Newsdesk","og_description":"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar BEIJING&#8211;(BUSINESS WIRE)&#8211; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH) sponsored a Science\/AAAS Webinar, \u201cEarly cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment\u201d, which launched today. During the panel discussion, Genetron Health\u2019s Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled \u201cProfiling cfDNA-based Biomarkers for the Early Detection of Cancer\u201d. In his presentation, Dr. Jiao highlighted the importance of early detection as the most effective method to prevent deaths from cancer. He also outlined the development and features of the Company\u2019s proprietary early screening technology, Mutation Capsule; presented a multi-center prospective study that adopted the Company\u2019s liquid biopsy-based early &hellip; Continue reading \"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T10:42:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar","datePublished":"2021-04-01T10:42:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/"},"wordCount":715,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/","name":"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-01T10:42:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-presented-its-proprietary-early-screening-technology-mutation-capsule-at-science-aaas-webinar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science\/AAAS Webinar"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469412"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}